Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
International Extranodal Lymphoma Study Group (IELSG) |
---|---|
Information provided by: | International Extranodal Lymphoma Study Group (IELSG) |
ClinicalTrials.gov Identifier: | NCT00210392 |
The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR
Condition | Intervention | Phase |
---|---|---|
Lymphoma, Mucosa-Associated Lymphoid Tissue |
Drug: Bortezomib (drug) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142) |
Enrollment: | 12 |
Study Start Date: | July 2005 |
Study Completion Date: | November 2007 |
Estimated Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
for primary gastric localized H. pylori-positive disease at diagnosis:
Exclusion Criteria:
Switzerland | |
Oncology Institute of Southern Switzerland (IOSI) | |
Bellinzona, Switzerland, 6500 |
Study Chair: | Franco Cavalli | International Extranodal Lymphoma Study Group |
Responsible Party: | IELSG ( International Extranodal Lymphoma Study Group (IELSG) ) |
Study ID Numbers: | IELSG25B |
Study First Received: | September 13, 2005 |
Last Updated: | July 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00210392 History of Changes |
Health Authority: | Switzerland: Swissmedic |
Lymphoma, B-Cell Lymphatic Diseases Immunoproliferative Disorders B-cell Lymphomas Bortezomib |
Lymphoma, B-Cell, Marginal Zone Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Protease Inhibitors |
Neoplasms by Histologic Type Immunoproliferative Disorders Molecular Mechanisms of Pharmacological Action Immune System Diseases Antineoplastic Agents Bortezomib Enzyme Inhibitors Lymphoma, B-Cell, Marginal Zone Pharmacologic Actions |
Protease Inhibitors Lymphoma, B-Cell Lymphatic Diseases Neoplasms Therapeutic Uses Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |